Pleural mesothelial cells in pleural and lung diseases.
Open accessThe DOI matches its OpenAlex record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
During development, the mesoderm maintains a complex relationship with the developing endoderm giving rise to the mature lung. Pleural mesothelial cells (PMCs) derived from the mesoderm play a key role during the development of the lung. The pleural mesothelium differentiates to give rise to the endothelium and smooth muscle cells via epithelial-to-mesenchymal transition (EMT). An aberrant recapitulation of such developmental pathways can play an important role in the pathogenesis of disease processes such as idiopathic pulmonary fibrosis (IPF). The PMC is the central component of the immune responses of the pleura. When exposed to noxious stimuli, it demonstrates innate immune responses such as Toll-like receptor (TLR) recognition of pathogen associated molecular patterns as well as causes the release of several cytokines to activate adaptive immune responses. Development of pleural effusions occurs due to an imbalance in the dynamic interaction between junctional proteins, n-cadherin and β-catenin, and phosphorylation of adherens junctions between PMCs, which is caused in part by vascular endothelial growth factor (VEGF) released by PMCs. PMCs play an important role in defense mechanisms against bacterial and mycobacterial pleural infections, and in pathogenesis of malignant pleural effusion, asbestos related pleural disease and malignant pleural mesothelioma. PMCs also play a key role in the resolution of inflammation, which can occur with or without fibrosis. Fibrosis occurs as a result of disordered fibrin turnover and due to the effects of cytokines such as transforming growth factor-β, platelet-derived growth factor (PDGF), and basic fibroblast growth factor; which are released by PMCs. Recent studies have demonstrated a role for PMCs in the pathogenesis of IPF suggesting their potential as a cellular biomarker of disease activity and as a possible therapeutic target. Pleural-based therapies targeting PMCs for treatment of IPF and other lung diseases need further exploration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 2×
“Crocidolite asbestos has been shown to induce PDGF mediated fibroblast proliferation in the pleura (98).”
BackgroundKing, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Delves, P. J., & Roitt, I. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007063430107 · Cited by 1,666
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039 · cited 1×
“Fibrotic remodeling in IPF occurs by mesenchymal cell proliferation and the differentiation of progenitor cells into myofibroblasts, which secrete excessive amounts of extracellular matrix resulting in scarring and destruction of the lung architecture (46,186,187).”
BackgroundPDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis
Boström, H., Willetts, K., Pekny, M., Levéen, P., Lindahl, P., Hedstrand, H., Pekna, M., Hellström, M., Gebre-Medhin, S., Schalling, M., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81270-2 · Cited by 864
Aberrant Wnt/β-Catenin Pathway Activation in Idiopathic Pulmonary Fibrosis
Chilosi, M., Poletti, V., Zamò, A., Lestani, M., Montagna, L., Piccoli, P., Pedron, S., Bertaso, M., Scarpa, A., Murer, B., et al. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64282-4 · Cited by 708
Lung development: orchestrating the generation and regeneration of a complex organ
Herriges, M., & Morrisey, E. E. (2014) · Development · doi:10.1242/dev.098186 · Cited by 613
Expression of adhesion molecules and chemotactic cytokines in cultured human mesothelial cells.
Jonjić, N., Peri, G., Bernasconi, S., Sciacca, F. L., Colotta, F., Pelicci, P., Lanfrancone, L., & Mantovani, A. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.4.1165 · Cited by 290
Mizuno, S., Matsumoto, K., Li, M.-Y., & Nakamura, T. (2005) · The FASEB Journal · doi:10.1096/fj.04-1535fje · Cited by 177 · cited 1×
“Increasing HGF levels in the lung and other organs enhances repair and slows the progression of fibrosis (159-166), while inhibition of HGF by neutralizing antibodies increases fibrosis (167).”
BackgroundZhou, B., von Gise, A., Ma, Q., Hu, Y. W., & Pu, W. T. (2010) · Developmental Biology · doi:10.1016/j.ydbio.2009.12.007 · Cited by 163 · cited 2×
“In lineage labeling studies, using Wt1 as a marker, PMCs were found to track into the lung parenchyma and undergo mesothelialmesenchymal transition (MMT) to form smooth muscle cells of the vascular wall, as well as other cells of the lung mesenchyme during development (7,20,41).”
BackgroundMethod
Cited by
Epithelial–Mesenchymal Transition in the Pathogenesis of Idiopathic Pulmonary Fibrosis
Salton, F., Volpe, M., & Confalonieri, M. (2019) · Medicina · doi:10.3390/medicina55040083 · Cited by 261
Elastin in lung development and disease pathogenesis
Mecham, R. P. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.01.005 · Cited by 208
Ibrahim, L. I., Hajal, C., Offeddu, G. S., Gillrie, M. R., & Kamm, R. D. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121728 · Cited by 53
Gulino, G. R., Polimeni, M., Prato, M., Gazzano, E., Kopecka, J., Colombatto, S., Ghigo, D., & Aldieri, E. (2016) · Environmental Health Perspectives · doi:10.1289/ehp.1409627 · Cited by 22
Metadata
- Authors
- Batra, H., & Antony, V. B.
- Venue
- PubMed
- Publisher
- National Institutes of Health
- Published
- 2015-06-01
- Volume
- 7
- Issue
- 6
- Pages
- 964-80
- OpenAlex
- W1942297034
- Cited by
- 80
- References
- 10
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pleural mesothelial cells in pleural and lung diseases. https://app.cochat.ai/papers/10.3978/j.issn.2072-1439.2015.02.19
- The paper
- Batra, H., & Antony, V. B. (2015). Pleural mesothelial cells in pleural and lung diseases. PubMed. https://doi.org/10.3978/j.issn.2072-1439.2015.02.19
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.